Methylation of RARß is a New Clinical Biomarker for Treatment in Higher‑grade Gliomas

TOPRAK Ç., ATLI E. İ., Kalkan R.

Neurological Sciences and Neurophysiology, vol.40, no.3, pp.152-159, 2023 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 3
  • Publication Date: 2023
  • Doi Number: 10.4103/nsn.nsn_26_23
  • Journal Name: Neurological Sciences and Neurophysiology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.152-159
  • Keywords: Glioma treatment, RARß, temozolomide
  • Trakya University Affiliated: Yes

Abstract

Background: The dysregulation of various pathways and cellular processes contributes to the carcinogenic transition from low‑grade gliomas to high‑grade gliomas. The altered tumor microenvironment, altered epigenetic state, and high mutation heterogeneity are critical factors in glial tumors. The morphogen retinoic acid (RA) controls the homeostasis, regeneration, and development of the brain. RA receptor (RAR) gene methylation has been shown in different types of glial tumors. Aims and Objectives: This study assessed the RARß gene as a potential therapeutic target in gliomas. Materials and Methods: Using in silico methods, potential drugs targeting the RARß gene were compared based on temozolomide’s effectiveness in treating gliomas. Results and Conclusion: Computational techniques can be used to identify drug‑mediated pathways. This in silico study holds promise for RARB and RARB‑targeted treatment strategies in gliomas.